Monique Celeste Tavares on Muck Rack

Monique Celeste Tavares

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Monique Celeste

Contact Monique Celeste, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort

|
By Monique Celeste Tavares, Romualdo Barroso-Sousa, Laura Testa, Pablo Mandó, Natalia Nunes, Matheus Andrade, Mariana Gouveia, Fernanda Madasi, José Bines, Rafael Ferreira, Daniela D Rosa, Mariana Monteiro, Daniele Assad-Suzuki, Carlos dos Anjos, Débora Gagliato, Ana Gomes, Bruna Zucchetti, Anezka Ferrari, Noéle Gomes, María Victoria Costanzo, Solange Moraes Sanches, Fabiana Makdissi, Paulo M Hoff, Renata Colombo Bonadio, Flávia C. Balint, Sergio Alejandro Mazzotta, Micaela Rigesti, Isadora. M. Sousa, Candice L. Santos, Zenaide S. Souza, Mayana L. Brito, Maria Marcela F. Monteiro, Gilmara Resende, Vladmir C. Lima
| Nature
Abstract Neoadjuvant pembrolizumab plus chemotherapy improves outcomes in early triple-negative breast cancer, but real-world evidence in patients with pathogenic BRCA1/2 variants remains limited. We analyzed 726 consecutively treated patients from the multicenter Neo-Real/GBECAM-0123 cohort who received at least one cycle of neoadjuvant pembrolizumab plus chemotherapy and underwent surgery.
Open in Who Shared Issue with article?

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123 | npj Breast Cancer

|
By Mariana Gouveia, Romualdo Barroso-Sousa, Laura Testa, Giuliana Colucci, Daniele Assad-Suzuki, Daniela Dornelles Rosa, José Bines, Candice Lima Santos, Mariana Monteiro, Bruna Zucchetti, Solange Moraes Sanches, Paulo M Hoff, Renata Colombo Bonadio, Laura Lapuchesky, Monique Celeste Tavares, Flávia Cavalcanti Balint, Débora de Melo Gagliato, Mayana Lopes de Brito, Isadora Martins de Sousa, Matheus de Oliveira Andrade, Fernanda Madasi, Mariana Savignano, Maira Tavares, Zenaide Silva de Souza, Anezka Ferrari, Poliana Albuquerque Signorini, Claudio Paletta
| Nature
Abstract The KEYNOTE-522 regimen is the standard of care for stage II–III triple-negative breast cancer (TNBC). However, older patients were underrepresented in the pivotal trial. We evaluated the effectiveness and safety of this regimen in patients aged ≥65 years enrolled in the Neo-Real/GBECAM-0123 multicenter real-world study conducted across institutions in Brazil and Argentina.
Open in Who Shared Issue with article?
See all 2 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Monique Celeste

Contact Monique Celeste, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified